Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study)

June 29, 2022 updated by: Institut National de la Santé Et de la Recherche Médicale, France

Pathologies métaboliques et Infectieuses en Population générale à La Réunion : étude REUNION

The aim of the present study is to determine the prevalence of cardiometabolic and infectious disease in La Reunion (french oversea department and region of France).

Known or suspected risk factor for these diseases will also be assessed, such as microbiota, cognitive impairement, social inequalities, and genetics.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Overall, 2000 men and women will be recruited during two years for an extensive clinical examination including a microbiota, blood, hair and DNA collection, cognitive tests, autonomous nervous system assessment, spirometry, pulse wave velocity measurement, a carotid doppler echo tracking.

Study Type

Observational

Enrollment (Anticipated)

2000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
    • Saint-Pierre
      • La Réunion, Saint-Pierre, France, 97448
        • Recruiting
        • Centre Hospitalier Universitaire de la Réunion

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 67 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Adult men and women ramdomly selected from the voter registration lists in La Réunion island

Description

Inclusion Criteria:

  • 18-67 years
  • given consent for genetic analysis,
  • written consent for participating in the study

Exclusion Criteria:

  • judicial protection or guardianship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
general population
Observational study of 2000 adult men and women from the general population who will benefit from a free extensive health check up in La Reunion
Diagnostic test: Blood, DNA, feces, urine, hair and skin microbiota collection
See above
Other Names:
  • Spirometry
  • EKG
  • pulse wave velocity measurement
  • Ewing test
  • cognitive, anxiety and depression tests
  • carotid ultrasound
  • ankle brachial index measurement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of cardiometabolic diseases
Time Frame: cross sectional (at inclusion)
Prevalence rates for diabetes, hypertension, obesity, dyslipidemia, smoking and subclinical atherosclerosis markers
cross sectional (at inclusion)
Prevalence of infectious diseases
Time Frame: cross sectional (at inclusion)
Seroprevalence rates for chikungunya, dengue, zika, covid19
cross sectional (at inclusion)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Investigators

  • Principal Investigator: Maxime COURNOT, MD, PhD, Institut National de la Santé Et de la Recherche Médicale, France
  • Study Director: Olivier MEILHAC, PhD, Institut National de la Santé Et de la Recherche Médicale, France
  • Study Director: Patrick MAVINGUI, PhD, Institut National de la Santé Et de la Recherche Médicale, France

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2022

Primary Completion (Anticipated)

May 1, 2024

Study Completion (Anticipated)

May 1, 2024

Study Registration Dates

First Submitted

May 27, 2022

First Submitted That Met QC Criteria

May 27, 2022

First Posted (Actual)

June 2, 2022

Study Record Updates

Last Update Posted (Actual)

July 5, 2022

Last Update Submitted That Met QC Criteria

June 29, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • C19-68
  • 2020A0209435 (Registry Identifier: IDRCB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on Blood, DNA, feces, urine, hair and skin microbiota collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe